 I'm Dom Savino with your Money Now. Shares of two of the world's largest drug makers are moving in opposite directions today. It's all because of a new data analysis showing Eli Lilly's popular obesity drug, Monjaro, leads to faster and greater weight loss than Novo Nordisk's treatment, Wegovi. The drugs have different active ingredients, and the report found patients taking Monjaro were twice as likely to lose at least 10%.